Ascendis Pharma
Ascendis Pharma is applying its innovative TransCon technologies to build a leading, fully integrated biopharmaceutical company focused on making a meaningful.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor investor | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | $150m | Post IPO Debt | |
| Total Funding | 000k | ||
| EUR | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 12 % | 558 % | 421 % | 36 % | 99 % | 78 % | 44 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (5447 %) | (1091 %) | (164 %) | (73 %) | (17 %) | 21 % | 32 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (4932 %) | (1140 %) | (181 %) | (104 %) | (16 %) | 20 % | 34 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 3804 % | 742 % | 155 % | 84 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Ascendis Pharma is a biopharmaceutical company that applies its TransCon technology platform to develop new therapies. The company's pipeline includes product candidates for endocrinology rare diseases and oncology.
The company is focused on creating prodrug therapies that are designed to improve upon existing treatments. Ascendis Pharma has several prodrug therapies in clinical development, both on its own and with partners.
Ascendis Pharma is headquartered in Copenhagen, Denmark, and has a global presence. The company is publicly traded on the Nasdaq stock exchange.
Keywords: biopharmaceutical, TransCon technology, endocrinology, rare diseases, oncology, prodrug therapies, clinical development, drug delivery, specialty pharma, drug development
Tech stack
Investments by Ascendis Pharma
Edit